BioCentury
ARTICLE | Company News

Lonsurf sales and marketing update

December 7, 2016 10:28 PM UTC

Germany’s Institute for Quality and Efficiency in Health Care (IQWiG) said in an early benefit assessment that Servier's Lonsurf trifluridine/tipiracil provides "a hint of minor added benefit" vs. best supportive care to treat metastatic colorectal cancer (mCRC) in patients with wild-type K-Ras (KRAS) tumors. IQWiG found Lonsurf provided considerable survival benefit in these patients but also greater harm of severe side effects. The agency said added benefit was not proven in mCRC patients with KRAS mutation because Lonsurf's survival advantage was less pronounced in the tumor type and outweighed by the severe side effects. IQWiG noted that Servier did not provide data on health-related quality of life, an outcome the agency considers “of major importance.” ...